Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities: 2022-2024

Historic Other Non-Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 2 years, with Jun 2024 value amounting to $35.6 million.

  • Rhythm Pharmaceuticals' Other Non-Current Liabilities rose 2596.67% to $35.6 million in Q2 2024 from the same period last year, while for Jun 2024 it was $35.6 million, marking a year-over-year increase of 2596.67%. This contributed to the annual value of $1.1 million for FY2023, which is 14.18% down from last year.
  • Rhythm Pharmaceuticals' Other Non-Current Liabilities amounted to $35.6 million in Q2 2024, which was up 2.88% from $34.6 million recorded in Q1 2024.
  • Over the past 5 years, Rhythm Pharmaceuticals' Other Non-Current Liabilities peaked at $35.6 million during Q2 2024, and registered a low of $1,000 during Q1 2023.
  • Its 3-year average for Other Non-Current Liabilities is $8.6 million, with a median of $1.3 million in 2023.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Other Non-Current Liabilities declined by 16.98% in 2023, and later skyrocketed by 3,459,700.00% in 2024.
  • Rhythm Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $1.3 million in 2022, then declined by 14.18% to $1.1 million in 2023, then skyrocketed by 2,596.67% to $35.6 million in 2024.
  • Its Other Non-Current Liabilities was $35.6 million in Q2 2024, compared to $34.6 million in Q1 2024 and $1.1 million in Q4 2023.